|Table of Contents|

Progress in the application of cytokines in the diagnosis and treatment of differentiated thyroid carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 05
Page:
939-942
Research Field:
Publishing date:

Info

Title:
Progress in the application of cytokines in the diagnosis and treatment of differentiated thyroid carcinoma
Author(s):
LIU Shuang; ZHOU Chunyan; DUAN Dong
Department of Nuclear Medicine，the First Affiliated Hospital of Chongqing Medical University，Chongqing 400016，China.
Keywords:
differentiated thyroid carcinoma(DTC); cytokines（CK）; diagnosis; prognosis; treatment
PACS:
R736.1
DOI:
10.3969/j.issn.1672-4992.2022.05.039
Abstract:
Thyroid carcinoma is one of the most common endocrine malignant tumors,and its incidence rate is increasing with years.Differentiated thyroid carcinoma(DTC)is the main type of thyroid carcinoma.Although most DTC patients have good prognosis after standardized treatment,due to the high invasiveness of pathological types or the loss of histological differentiation,the disease progresses rapidly,resulting in a significant reduction in the life span of patients.In recent years,there are more and more studies on the relationship between inflammation and tumor,and the role of inflammatory microenvironment in the pathogenesis of tumor been gradually confirmed.More evidence show that cytokines can be used as an important reference for the differentiation between benign and malignant tumors,prediction of prognosis and preference of diagnosis and treatment.In this paper,the application of some cytokines in DTC is reviewed,aiming to provide reference for the diagnosis,treatment and prognosis of thyroid carcinoma.

References:

[1] 中华人民共和国国家卫生健康委员会.甲状腺癌诊疗规范(2018年版)［J］.中华普通外科学文献(电子版),2019,13(01):1-15. National Health Commission of the PRC.Standard for diagnosis and treatment of thyroid cancer［J］.Chinese Archives of General Surgery(Electronic Edition),2019,13(01):1-15.
[2] COOPER DS,DOHERTY GM,HAUGEN BR,et al.Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer:the american thyroid association(ATA)guidelines taskforce on thyroid nodules and differentiated thyroid cancer［J］.Thyroid Official Journal of the American Thyroid Association,2009,19(11):1167-1214.
[3] BALKWI LL,FRA N,MANTOVA NI,et al.Inflammation and cancer:back to Virchow［J］.Lancet,2001,359(9255):539-545.
[4] CABANILLAS ME,MCFADDEN DG,DURANTE C.Thyroid cancer［J］.Lancet,2016,388(10061):2783.
[5] DRENKA T,JELENA K,OKI DI,et al.The roles of mesenchymal stromal/stem cells in tumor microenvironment associated with inflammation［J］.Mediators of Inflammation,2016,2016:1-14.
[6] LANDSKRON G,MARJORIE DLF,THUWAJIT P,et al.Chronic inflammation and cytokines in the tumor microenvironment［J］.J Immunol Res,2014,2014:1-19.
[7] LIN P,GUO YN,SHI L,et al.Development of a prognostic index based on an immunogenomic landscape analysis of papillary thyroid cancer.［J］.Aging(Albany NY),2019,11(2):480-500.
[8] WANG D,N DR.Immunosuppression associated with chronic inflammation in the tumor microenvironment［J］.Carcinogenesis,2015,36(10):1085-1093.
[9] LIMA PCM,MOURA NETO A,TAMBASCIA MA,et al.Risk factors associated with benign and malignant thyroid nodules in autoimmune thyroid diseases［J］.Isrn Endocrinology,2013,2013:1-7.
[10] BERGDORF KN,FERGUSON DC,MEHRAD M,et al.Papillary thyroid carcinoma behavior:clues in the tumor microenvironment［J］.Endocrine Related Cancer,2019,26(6):601-604.
[11] FEDERICA L,CARLA V,MARINA MR.Inflammation in thyroid oncogenesis［J］.American Journal of Cancer Research,2012,2(3):286-297.
[12] LEITE CL,ALANA MM,STERIAN WL.The role of the inflammatory microenvironment in thyroid carcinogenesis［J］.Endocrine-Related Cancer,2014,21(3):85-103.
[13] SUN WC,KIM YA,SUN HJ,et al.CXCL16 signaling mediated macrophage effects on tumor invasion of papillary thyroid carcinoma［J］.Endocr Relat Cancer,2015,23(2):113-124.
[14] BRYAN R,HAUGEN EKAK,YURI E,et al.2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer［J］.Thyroid,2016,26(1):131-133.
[15] 康海岩,杨庭显,张磊,等.甲状腺癌患者血清Gal-3、IL-17、IL-35、anti-TgAb的变化及其意义［J］.西北国防医学杂志,2017,38(8):505-508. KANG HY,YANG TX,ZHANG L,et al.Significance of serum Gal-3,IL-17,IL-35 and anti-TgAb in patients with thyroid carcinoma［J］.Medical Journal of National Defending Forces in Northwest China,2017,38(8):505-508.
[16] 魏伟,赵黎.甲状腺癌患者血清IL-17、SIL-2R及TG水平及其临床意义分析［J］.湖南师范大学学报(医学版),2020,17(02):24-27. WEI W，ZHAO L.Serum IL-17、SIL-2R and TG levels in patients with thyroid carcinoma and its clinical significance［J］.Journal of Hunan Normal University(Medical Science),2020,17(02):24-27.
[17] 张海涛,薛伶俐.IL-17、IL-35在甲状腺癌患者血清中的表达及临床意义［J］.中国现代医生,2016,54(15):99-101. ZHANG HT,XUE LL.Expression and clinical significance of IL-17,IL-35 in serum of thyroid cancer patients［J］.China Modern Doctor,2016,54(15):99-101.
[18] 叶卫丰,贺敏,苏建荣，等.IL-17和IL-35在甲状腺癌患者血清中的水平及临床意义［J］.临床和实验医学杂志,2015,14(01):32-35. YE WF,HE M,SU JR，et al.Serum IL-17,IL-35 levels and clinical significance in patients with thyroid cancer［J］.Journal of Clinical and Experimental Medicine,2015,14(01):32-35.
[19] 屠燕,沈美萍,秦瑞浩,等.IL-17在甲状腺乳头状癌中的表达与临床意义［J］.南京医科大学学报(自然科学版),2013,33(04):485-489. TU Y,SHEN MP,QIN RH,et al The expression of IL-17 in papillary thyroid carcinoma and its clinical significance［J］.Journal of Nanjing Medicial University，2013,33(04):485-489.
[20] 刘杨,吴高松,王文斌,等.血清IL-17、IL-35及SIL-2R表达水平与甲状腺癌发生发展的关系［J］.肿瘤防治研究,2016,43(09):789-791. LIU Y,WU GS,WANG WB,et al.Relationship of serum IL-17,IL-35,SIL-2R levels with occurrence and development of thyroid cancer［J］.Cancer Research on Prevention and Treatment,2016,43(09):789-791.
[21] HONG SHENG,LU LZYD,CHEN Q.Markers of immune activation:novel biomarkers to predict the early-warning indicator of patients with papillary thyroidcarcinoma［J］.Diagnostic Pathology,2020,15:16.
[22] TORAL P.KOBAWALA,TRUPTI I.TRIVEDI,et al.Significance of TNF-and the adhesion molecules:l-selectin and VCAM-1 in papillary thyroid carcinoma［J］.Journal of Thyroid Research,2016,2016:8143695.
[23] KOBAWALA TORAL P,TRIVEDI TRUPTI I,GAJJAR KINJAL K,et al.Significance of interleukin-6 in papillary thyroid carcinoma［J］.Journal of Thyroid Research,2016,2016:6178921.
[24] ZHOU D.BRAF V600E and RET/PTC promote the activityof nuclear factor-kB,inflammatory mediators,and lymph node metastasis in papillary thyroid carcinoma:a study of 50 patients in inner mongolia［J］.Med Sci Monit,2018,24:6795-6808.
[25] DENISE FARIA GALANO CARVALHO BRZL,MARCELA KAZUE HASSUMI FUKASAWA F MC,SOARES JCOC.High IL-17 expression is associated with an unfavorable prognosis in thyroid cancer［J］.Oncology Letters,2017,13(3):1925-1931.
[26] SHIMIN WANG ZALA.Prognostic role of intratumoral IL-17A expression byimmunohistochemistry in solid tumors:a meta-analysis［J］.Oncotarget,2017,8(39):66382-66391.
[27] 胡金华,张耀晴,艾瑞华,等.分化型甲状腺癌患者血清TNF-α、IL-6和VEGF表达与侵袭转移的相关性分析［J］.现代肿瘤医学,2015,23(06):771-774. HU JH,ZHANG YQ,AI RH,et al.Correlation of serum TNF-α IL-6 and VEGF of patients with differentiated thyroid carcinoma and its invasion and metastasis［J］.Modern Oncology,2015,23(06):771-774.
[28] 姜兴莲,张徽,陈晏林,等.microRNA-221及白细胞介素-17在甲状腺乳头状癌中的表达及相关性［J］.中华病理学杂志,2017,46(3):160-165. JIANG XL,ZHANG H,CHEN YL,et al.Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features［J］.Chinese Journal of Pathology,2017,46(3):160-165.
[29] HAN LT,HU JQ,MA B,et al.IL-17A increases MHC class I expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto’s thyroiditis［J/OL］.Diagnostic Patholog,2019,14(1):52［2019-06-04］.https://pubmed.ncbi.nlm.nih.gov/31159823/.DOI:10.1186/s13000-019-0832-2.
[30] LUCAS LEITE CUNHA ELAINE CRISTINA MORARI SNMA.Interleukin 10 expression is related to aggressiveness and poorprognosis of patients with thyroid cancer［J］.Cancer Immunol Immunother,2017,66:141-148.
[31] LUO GZCS.High expression of interleukin-12a and its association with the clinicopathology and prognosis of differentiated thyroid cancer［J］.Eur Thyroid J,2020,9(3):1-9.
[32] NANNAN LV Y GHG.Inflammatory mediators,tumor necrosis factor-α andinterferon-γ,induce EMT in human PTC cell lines［J］.Oncology Letters,2015,10（4）：2591-2597.
[33] BERTOL BC,JESSICA NAYARA GOES DE ARAUJO,SADISSOU IA,et al.Plasma levels of soluble HLA-G and cytokines in papillary thyroid carcinoma before and after thyroidectomy［J］.International Journal of Clinical Practice,2020,74(10):e13585.
[34] 蒋雯,宋影春,罗琼,等.趋化因子水平变化在预测分化型甲状腺癌病情进展中的价值［J］.中华核医学与分子影像杂志,2020,40(5):288-293. JIANG W,SONG YC,LUO Q,et al.Value of chemokines levels in predicting the progression of differentiated thyroid carcinoma［J］.Chinese Journal of Nuclear Medicine and Molecular Imaging,2020,40(5):288-293.
[35] RENDONG ZHENG GCXL.Effect of IL-6 on proliferation of human thyroid anaplastic cancer stem cells［J］.Int J Clin Exp Pathol,2019,12(11):3992-4001.
[36] GU M.IL-13r-α-2 sirna inhibited cell proliferation,induced cell apoptosis,and suppressed cell invasion in papillary thyroid carcinoma cells［J］.Onco Targets and Therapy,2018,11:1345-1352.
[37] REN L,XU Y,LIU C,et al.IL-17RB enhances thyroid cancer cell invasion and metastasis via ERK1/2 pathway-mediated MMP-9 expression［J］.Molecular Immunology,2017,90:126-135.
[38] ZHANG P,ZHANG H,DONG W,et al.IL-34 is a potential biomarker for the treatment of papillary thyroid cancer［J］.Journal of Clinical Laboratory Analysis,2020,34(3):e23335.
[39] KUDO-SAITO C,MIYAMOTO T,IMAZEKI H,et al.IL33 is a key driver of treatment resistance of cancer［J］.Cancer Research,2020,80(10):2235.
[40] CHEN ZMLZ,LI XLLJ.Interleukin-22 promotes papillary thyroid cancer cell migrationand invasion through microRNA-595/Sox17 axis［J］.Tumor Biol,2016,37(9):11753-11762.
[41] WEI LI FLWL.TRIM30 modulates interleukin-22-regulated papillary thyroid cancer cell migration and invasion by targeting Sox17 for K48-linked polyubiquitination［J］.Cell Communication and Signaling,2019,17:162.
[42] YVETTE JE,SLOOT KATRIN RABOLD T,JOACHIM L SCHULTZE MGNJ.Interplay between thyroid cancer cells and macrophages:effects on IL-32 mediated cell death and thyroid cancer cell migration［J］.Cellular Oncology,2019,42:691-703.
[43] MARCIA FARIA,DOMINGUES R,PAIXO F,et al.TNFα-mediated activation of NF-κB downregulates sodium-iodide symporter expression in thyroid cells［J］.PLoS One,2020,15(2):e0228794.
[44] 刘日信，李建芳，曾凤伟，等.分化型甲状腺癌术后首次131I治疗时间选择对疗效的影响［J］.现代肿瘤医学，2018,26（19）：3042-3045. LIU RX,LI JF,ZENG FW,et al.Effect of time selection on initial 131I treatment in post-surgery patients with differentiated thyroid cancer［J］.Modern Oncolocy,2018,26（19）：3042-3045.

Memo

Memo:
重庆市自然科学基金（面上项目）（编号：cstc2019jcyj-msxmX0327）
Last Update: 2022-01-27